ArticleInvestigative ophthalmology & visual science2026
Targeted Ferroptosis Improves RPE Phagocytosis via MERTK/NFE2L2/HMOX1 Axis to Alleviate Retinitis Pigmentosa.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in ferroptosis and cuproptosis: implications for spinal cord injury.Molecular biology reports · 2026Review
- Non-Erythropoietic EPO (EPO-R76E) Protects RPE Cells from Ferroptosis by Modulating the Labile Iron Pool and NRF2-GPX4 Axis.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Retinitis pigmentosa (RP) is a heterogeneous inherited retinal disorder in which progressive rod and cone degeneration, together with retinal pigment epithelium (RPE) dysfunction, culminates in vision loss. Given the lack of effective therapies, we investigated RPE pathogenic alterations in RP models to inform potential therapeutic strategies. Methods: This study integrates Royal College of Surgeons (RCS) rat in vivo and human primary RPE cells in vitro to investigate the RP model. We employ single-cell RNA sequencing (scRNA-seq) to analyze the transcriptional differences in the retinas of RCS and RDY rats and to interrogate ferroptosis-related signal transduction. After treatment with the ferroptosis inhibitor Ferrostatin-1 (Fer-1) in both in vivo and in vitro RP models, therapeutic efficacy and RPE phagocytic function were assessed by using fundus photography, hematoxylin and eosin staining, electroretinography, Western blotting, immunofluorescence, and reverse transcription quantitative PCR. Results: Our scRNA-seq revealed marked transcriptional remodeling across retinal cell populations in RCS rats, with ferroptosis-related programs evident in most cell types and most pronounced in RPE. NFE2L2 and HMOX1 were significantly upregulated in RCS rats and in vitro MERTK-deficient RP models. Fer-1 ameliorated cytoskeletal disorganization and restored RPE phagocytic function, whereas selective silencing of NFE2L2 or HMOX1 reduced iron overload and rescued cytoskeletal integrity and phagocytosis, supporting a pathogenic role for ferroptosis in RP. Conclusions: Ferroptosis is a critical driver of MERTK-deficient RP, influencing RPE dysfunction through the MERTK/NFE2L2/HMOX1 axis. These insights highlight the potential therapeutic strategy of targeting ferroptosis to regulate RPE function in the treatment of MERTK-deficient RP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.